big crypto currencies Top See results about

The US dollar just hit the 7.2700 yuan mark against the offshore RMB, and the latest price was 7.2700 yuan, down 0.10% in the day. The US dollar against the onshore RMB was recently reported at 7.2660 yuan, up 0.06% in the day.Gobi Venture Capital announced in Shanghai that it will launch a $50 million venture capital fund to support Pakistan's technology start-ups. On December 12th, at the Pakistan Investment Summit held in Shanghai, Gobi Venture Capital, an Asian venture capital company, officially announced the launch of a $50 million fund Techxila Fund II to support Pakistan's start-ups, focusing on high-potential industries such as financial technology, e-commerce logistics and supply chain, health technology and SaaS. Gobi Venture Capital also signed a memorandum of understanding with Punjab Bank (BoP). (First Financial Reporter Qian Tongxin)Kweichow Moutai traded 28,300 shares today, with a turnover of 44,312,100 yuan. Kweichow Moutai traded 28,300 shares today, with a turnover of 44,312,100 yuan, accounting for 0.68% of the total turnover of the day. The transaction price was 15.658 yuan, which was the same as the market closing price of 15.658 yuan.

Lu 'an Huaneng: The raw coal output in November was 5.09 million tons, down 5.39% year-on-year. Lu 'an Huaneng announced that the raw coal output in November 2024 was 5.09 million tons, down 5.39% year-on-year; The sales volume of commercial coal was 5.36 million tons, up 18.32% year-on-year. In 2024, the cumulative output of raw coal was 52.25 million tons, down 4.88% year-on-year; The cumulative sales volume of commercial coal was 47.09 million tons, down 4.48% year-on-year.German Foreign Minister: Ukraine needs hard security.Tiankang Bio: Tiankang Bio (002100) announced on the evening of December 12 that Tiankang Bio (stock code: 874339), a holding subsidiary of the company, intends to apply for public offering of shares to unspecified qualified investors and listing on the Beijing Stock Exchange. As of the disclosure date of the announcement, Tiankang Bio's public offering of shares to unspecified qualified investors and listing on the North Stock Exchange are under counseling.

 18 shares were rated by brokers, and Yuhetian's target increased by 54.72%. On December 11th, a total of 18 shares were rated by brokers, and 6 of them announced their target prices. According to the highest target price, Yuhetian, Steady Medical Care and Fulongma ranked in the top, with increases of 54.72%, 19.96% and 17.62% respectively. Judging from the direction of rating adjustment, the ratings of 12 stocks remain unchanged and 6 stocks are rated for the first time. In addition, one stock attracted the attention of many brokers, and Hagrid Communications was ranked in the top number, with two brokers rating it respectively. Judging from the Wind industry to which the rated stocks are bought, the number of rated stocks for technical hardware and equipment, capital goods and materials II is the largest, with 4, 3 and 2 respectively.CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.